Toxicogenomics of A375 human malignant melanoma cells

Pharmacogenomics

Volumn 8, Issue 8, 2007, Pages 1017-1036

  Cheng, Sun Long ^a   Huang Liu, Rosa ^a   Sheu, Jin Nan ^a   Chen, Shui Tein ^b,c   Sinchaikui, Supachok ^b   Tsay, Gregory J ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

A375 cells; Gene expression; Genotoxic effect; Microarray; Toxicogenomics

Indexed keywords

2 (3,5 DI TERT BUTYL 4 HYDROXYPHENYL) 1,1 ETHANEBISPHOSPHONIC ACID TETRAISOPROPYL ESTER; ANTINEOPLASTIC AGENT; ASCORBIC ACID; BORTEZOMIB; CAMPTOTHECIN; CCD 779; ENDOTHELIN 1; EPICATECHIN; EPIGALLOCATECHIN GALLATE; ERIANIN; EVODIAMINE; FUMARIC ACID DIMETHYL ESTER; GINSENOSIDE RH 2; HEPARIN; MONOCLONAL ANTIBODY LM 609; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; OBLIMERSEN; PD 032591; RESVERATROL; SORAFENIB; THALIDOMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BIOINFORMATICS; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE ARREST; CORRELATION ANALYSIS; DNA MICROARRAY; DRUG CYTOTOXICITY; DRUG RESEARCH; DRUG SAFETY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC DATABASE; GENOME ANALYSIS; GENOMICS; GENOTOXICITY; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MELANOGENESIS; MELANOMA; MITOSIS INHIBITION; NONHUMAN; PROTEOMICS; QUANTITATIVE ANALYSIS; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; SYSTEMS BIOLOGY; TOXICOGENOMICS;

ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; HUMANS; MELANOMA; TOXICOGENETICS;

EID: 34548794873     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.8.1017     Document Type: Review

References (102)

1. Soengas MS, Capodieci P, Polsky D et al.: Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409, 207-211 (2001).
2. Kaufmann SH, Vaux DL: Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 22, 7414-7430 (2003).
3. Pennie WD, Tugwood JD, Oliver GJA, Kimber I: The principles and practical of toxicogenomics: applications and opportunity. Toxicol. Sci. 54. 277-283 (2000).
4. Waters MD, Fostel JM: Toxicogenomics a systems toxicology: aims and prospects. Nature 5, 936-948 (2004).
5. Boverhof DR, Zacharewski TR: Toxicogenomics in risk assessment: applications and needs. Toxicol. Sci. 89, 352-360 (2006).
6. de Braud F, Khayat D, Kroon BB, Valdagni R, Bruzzi P, Cascinelli N: Malignant melanoma. Crit. Rev. Oncol. Hematol. 47, 35-63 (2003).
7. Slominski A, Tobin DJ, Shibahara S, Wortsman J: Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol. Rev. 84, 1155-1228 (2004).
8. Shibata T, Prota G, Mishima Y: Non-melanosomal regulatory factors in melanogenesis. J. Invest. Dermatol. 100, S274-S280 (1993).
9. Clark EA, Golub TR, Lander ES, Hynes RO: Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406, 532-535 (2000).
10. Bodzioch M, Dembinska-Kiec A, Hartwich J et al.: The microarray expression analysis identifies BAX as mediator of β-carotene effects on apoptosis. Nutr. Cancer 51, 226-235 (2005).
11. Cheng SL, Huang Liu R, Sheu JN, Chen ST, Sinchaikul S, Tsay GJ: Toxicogenomics of kojic acid on gene expression profiling of A375 human malignant melanoma cells. Biol. Pharm. Bull. 29, 655-669 (2006).
12. Cheng SL, Huang Liu R, Sheu JN, Chen ST, Sinchaikul S, Tsay GJ: Toxicogenomics of A375 human malignant melanoma cells treated with arbutin. J. Biomed. Sci. 14, 87-105 (2007).
13. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE: Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338, 1227-1229 (1991).
14. Brossart P, Schmier JW, Krüger S et al.: A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. Cancer Res. 55. 4056-4068 (1995).
15. Battayani Z, Grob JJ, Xerri L et al.: Polymerase chain reaction detection of circulating melanocytes; as a prognostic marker in patients with melanoma. Arch. Dermatol. 131. 443-447 (1995).
16. Keilhoiz U, Goldin-Lang P, Bechrakis NE et al.: Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction. Clin. Cancer Res. 10. 1605-1612 (2004).
17. Hannon GJ: RNA interference. Nature 418(6894), 244-251 (2002).
18. Sumimoto H, Miyagishi M, Miyoshi H et al.: Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 23, 6031-6039 (2004).
19. Hoeflich KP, Gray DC, Eby MT et al.: Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res. 66, 999-1006 (2006).
20. Chen X, Lin J, Kanekura T, Su J: A small interfering CD147-targeting RNA inhibited the proliferation, invasiveness, and metastatic activity of malignant melanoma. Cancer Res. 66, 11323-11330 (2006).
21. Tao J, Tu YT, Huang CZ, et al.: Inhibiting the growth of malignant melanoma by blocking the expression of vascular endothelial growth factor using an RNA interference approach. Br J. Dermatol. 153. 715-724 (2005).
22. Yazdi AS, Morstedt K, Puchta U et al.: Heterogeneity of T-cell clones infiltrating primary malignant melanomas. J. Invest, Dermatol. 126, 393-398 (2006).
23. Tanami H, Imoto I, Hirasawa A et al.: Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines. Oncogene 23, 8796-8804 (2004).
24. 1/S cell cycle in melanoma: TP53. CDKN1A, CDKN2A, and CDKN2B. BMC Cancer 5, 36 (2005).
25. Cervoni L, Egistelli L, Eufemi M et al.: DNA sequences acting as binding sites for NM23/NDPK proteins in melanoma M14 cells. J Cell. Biochem. 98, 421-428 (2006).
26. Anderson L, Seilhamer J: A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 18. 533-537 (1997).
27. Gygi SP, Rochon Y, Franza BR, Aebersold R: Correlation between protein and mRNA abundance in yeast. Mol. Cell. Biol. 19, 1720-1730 (1999).
28. Chen G, Gharib TG, Huang CC et al.: Discordant protein and mRNA expression in lung adenocarcinomas. Mol. Cell. Proteomics 1, 304-313 (2002).
29. Myung JK, Afjehi-Sadat L, Felizardo-Cabatic M, Slavc I, Lubec G: Expression patterns of chaperones in ten human tumor cell lines. Proteome Sci. 2, 8 (2004).
30. Clauser KR, Hall SC, Smith DM et al.: Rapid mass spectrometric peptide sequencing and mass matching for characterization of human melanoma proteins isolated by two-dimensional PAGE Proc. Natl Acad. Sci. USA 92, 5072-5076 (1995).
31. Mattingly CJ, Rosenstein MC, Colby GT, Forrest JN Jr. Boyer JL: The Comparative Toxicogenomics; Database (CTD): a resource for comparative toxicological studies. J. Exp. Zool. 305, 689-692 (2006).
32. Burgoon LD, Boutros PC, Dere E, Zacharewski TR: dbZach: A MIAME-compliant toxicogenomic supportive relational database. Toxicol. Sci. 90, 558-568 (2006).
33. Cascalho M: Advantages and disadvantages of cytidine deamination. J. Immunol. 172, 6513-6518 (2004).
34. Qi H, Fournier A, Grenier J, Fillion C, Labrie Y, Labrie C: Isolation of the novel human guanine nucleotide exchange factor Src homology 3 domain-containing guanine nucleotide exchange factor (SGEF) and of C-terminal SGEF, an N-terminally truncated form of SGEF, the expression of which is regulated by androgen in prostate cancer cells. Endocrinology 144, 1742-1752 (2003).
35. Kanai M, Goke M, Tsunekawa S, Podolsky DK: Signal transduction pathway of human fibroblast growth factor receptor 3. Identification of a novel 66-kDa phosphoprotein. J. Biol. Chem. 272, 6621-6628 (1997).
36. Chesi M, Brents LA, Ely SA et al.: Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 97, 729-736 (2001).
37. Meier F, Schittek B, Busch S et al.: The RAS/RAF/MEK/ERK and PI3K/ AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front. Biosci. 10, 2986-3001 (2005).
38. Laprise P, Langlois MJ, Boucher MJ, Jobin C, Rivard N: Down-regulation of MEK/ERK signaling by E-cadherin-dependent PI3K/Akt pathway in differentiating intestinal epithelial cells. J. Cell. Physiol. 199, 32-39 (2004).
39. Parsa AT, Holland EC: Cooperative translational control of gene expression by Ras and Akt in cancer. Trends Mol. Med. 10. 607-613 (2004).
40. Eswarakumar VP, Lax I, Schlessinger J: Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 16, 139-149 (2005).
41. Schneider WJ, Nimpf J: LDL receptor relatives at the crossroad of endocytosis and signaling. Cell. Mol. Life Sci. 60, 892-903 (2003).
42. Quaiser T, Anton R, Kuhl M: Kinases and G proteins join the Wnt receptor complex. Bioessays 28, 339-343 (2006).
43. Robertson GP: Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev. 24, 273-285 (2005).
44. Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A, Goel V: Genetic alterations in signaling pathways in melanoma. Clin. Cancer Res. 12, S2301-S2307 (2006).
45. Becker JC, Kirkwood JM, Agarwala SS, Dummer R, Schrama D, Hauschild A: Molecularly targeted therapy for melanoma: current reality and future options. Cancer 107, 2317-2327 (2006).
46. Chin L, Garraway LA, Fisher DE: Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev. 20, 2149-2182 (2006).
47. Alsina J, Gorsk DH, Germino FJ et al.: Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma. Clin. Cancer Res. 9, 6419-6425 (2003).
48. Smalley KS: A pivotal role for ERK in the oncogenic behaviour of malignant melanoma. Int. J Cancer 104, 527-532 (2003).
49. Weeraratna AT, A Wnt-er wonderland - the complexity of Wnt signaling in melanoma. Cancer Metastasis Rev. 24, 237-250 (2005).
50. Larue L, Delmas V: The WNT/β-catenin pathway in melanoma. Front. Biosci. 11. 733-742 (2006).
51. Pourpak A, Dorr RT, Meyers RO, Powell MB, Stratton SP: Cytotoxicity activity of apomine is due to a novel membrane-mediated cytolytic mechanism independent of apoptosis in the A375 human melanoma cell line. Invest. New Drugs 25, 107-114 (2007).
52. Costa MA, Penerito L, Izzo V et al.: Diorganotin (IV) and triorganotin (IV) complexes of meso-tetra (4-sulfonatophenyl) porphine induce apoptosis in A375 human melanoma cells. Cancer Lett. 238, 284-294 (2006).
53. Kolarova H, Mosinger J, Lenobel R, Kejlova K, Jirova D, Strnad M: In vitro toxicity testing of supramolecular sensitizers for photodynamic therapy. Toxicol. In Vitro 17, 775-778 (2003).
54. Ribble D, Goldstein NB, Norris DA, Shellman YG: A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol. 5, 12 (2005).
55. Pantazis P, Hinz HR, Mendoza JT et al.: Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res. 52, 3980-3987 (1992).
56. Wang F, Cao Y, Liu HY, Xu SF, Han R: Anti-invasion and anti-angiogenesis effect of taxol and camptothecin on melanoma cells. J. Asian Nat. Prod. Res. 5, 121-129 (2003).
57. Loewe R, Valero T, Kremling S et al.: Dimethylfumarate impairs melanoma growth and metastasis. Cancer Res. 66. 11888-11896 (2006).
58. Okazawa M, Shiraki T, Ninomiya H, Kobayashi S, Masaki T: Endothelin-induced apoptosis of A375 human melanoma cells. J. Biol. Chem. 273, 12584-12592 (1998).
59. Spinella F, Rosano L, Di Castro V et al.: Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1α in human melanoma cells. Cancer Res. 67, 1725-1734 (2007).
60. + currents. Cell Motil. Cytoskeleton 58, 127-136 (2004).
61. Lozano C, Torres JL, Julia L, Jimenez A, Centelles JJ, Cascante M: Effect of new antioxidant cysteinyl-flavanol conjugates on skin cancer cells. FEBS Lett. 579. 4219-4225 (2005).
62. Nihal M, Ahmad N, Mukhtar H, Wood GS: Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of malanoma. Int. J Cancer 114, 513-521 (2005).
63. Suzuki Y, Isemura M: Inhibitory effect of epigallocatechin gallate on adhesion of murine melanoma cells to laminin. Cancer Lett. 173, 15-20 (2001).
64. Gong YQ, Fan Y. Wu DZ, Yang H, Hu ZB, Wang ZT: In vivo and in vitro evaluation of erianin, a novel anti-angiogenic agent. Eur. J. Cancer 40, 1554-1565 (2004).
65. Zhang Y, Wu LJ, Tashiro SI, Onodera S, Ikejima T: Evodiamine induces tumor cell death through different pathways: apoptosis and necrosis. Acta Pharmacol. Sin. 25, 83-89 (2004).
66. 2 on human malignant melanoma. Acta Pharmacol. Sin. 23, 315-322 (2002).
67. 2 in cultured murine cells. Life Sci. 60, 39-44 (1997).
68. Wei M, Gao Y, Tian M, Li N, Hao S, Zeng X: Selectively desulfated heparin inhibits P-selectin-mediated adhesion of human melanoma cells. Cancer Lett. 229, 123-126 (2005).
69. Bereczky B, Gilly R, Raso E, Vago A, Timar J, Tovari J: Selective antimetastatic effect of heparins in preclinical human melanoma models is based on inhibition of migration and microvascular arrest. Clin. Exp. Metastasis 22, 69-76 (2005).
70. Stevenson JL, Choi SH, Varki A: Differential metastasis inhibition by clinically relevant levels of heparins - correlation with selectin inhibition, not antithromotic activity. Clin. Cancer Res. 11, 7003-7011 (2005).
71. Niles RM, McFarland M, Weimer MB, Redkar A, Fu YM, Meadows GG: Resveratrol is a potent inducer of apoptosis in human melanoma cells. Cancer Lett. 190, 157-163 (2003).
72. Fulda S, Debatin KM: Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res. 64, 337-346 (2004).
73. Hsieh TC, Wang Z, Hamby CV, Wu JM: Inhibition of melanoma cell proliferation by resveratrol is correlated with upregulation of quinine reductase 2 and p53. Biochem. Biophys. Res. Commun. 334, 223-230 (2005).
74. Lin SY, Lai WW, Chou CC et al.: Sodium ascorbate inhibits growth via the induction of cell cycle arrest and apoptosis in human malignant melanoma A375.S2 cells. Melanoma Res. 16, 509-519 (2006).
75. Kang JS, Cho D, Kim YI et al.: Sodium ascorbate (vitamin C) induces apoptosis in melanoma cells via the down-regulation of transferrin receptor dependent iron uptake. J. Cell. Physiol. 204, 192-197 (2005).
76. Kang JS, Cho D, Kim YI et al.: L-ascorbic acid (vitimin C) induces the apoptosis of B16 murine melanoma cells via a caspase-8-independent pathway. Cancer Immunol. Immunother. 52, 693-698 (2003).
77. DeRisi J, Penland L, Brown PO et al: Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Cenet. 14, 457-460 (1996).
78. Bittner M, Meltzer P, Chen Y et al.: Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406, 536-540 (2000).
79. Brem R, Hildebrandt T, Jarsch M, van Muijen GN, Weidle UH: Identification of metastasis-associated genes by transcriptional profiling of a metastasizing versus a non-metastasizing human melanoma cell line. Anticancer Res. 21, 1731-1740 (2001).
80. de Wit NJ, Burtscher HJ, Weidle UH, Ruiter DJ, van Muigen GN: Differentially expressed genes identified in human melanoma cell lines with different metastatic behavior using high-density oligonucleotide arrays. Melanoma Res. 12, 57-69 (2002).
81. Tschentscher F, Husing J, Hotter T et al.: Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res. 63, 2578-2584 (2003).
82. Hoek K, Rimm DL, Williams KR et al.: Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res. 64, 5270-5282 (2004).
83. Haqq C. Nosrati M, Sudilovsky D et al.: The gene expression signatures of melanoma progression. Proc. Natl Acad. Sci. USA 102, 6092-6097 (2005).
84. Nambiar S, Mirmohammadsadegh A. Doroudi R et al.: Signaling networks in cutaneous melanoma metastasis identified by complementary DNA microarrays. Arch. Dermatol. 141, 165-173 (2005).
85. Jaeger J, Koczan D, Thiesen HJ et al.: Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin. Cancer Res. 13, 806-815 (2007).
86. Bernard K, Litman E, Fitzpatrick JL et al.: Functional proteomic analysis of melanoma progression. Cancer Res. 63, 6716-6725 (2003).
87. Sinha P, Poland J, Kohl S et al.: Study of the development of chemoresistance in melanoma cell lines using proteome analysis. Electrophoresis 24, 2386-2404 (2003).
88. Craven RA, Stanley AJ, Hanrahan S et al.: Identification of proteins regulated by interferon-α in resistant and sensitive malignant melanoma cell lines. Proteomics 4, 3998-4009 (2004).
89. Chi A, Valencia JC, Hu ZZ et al.: Proteomic and bioinformatic characterization of the biogenesis and function of melanosomes. J. Proteome Res. 5, 3135-3144 (2006).
90. Culp WD, Neal R, Massey R, Egevad L, Pisa P, Garland D: Proteomic analysis of tumor establishment and growth in the B16-F10 mouse melanoma model. J. Proteome Res. 5, 1332-1343 (2006).
91. de Souza GA, Godoy LM, Teixeira VR et al: Proteomic and SAGE profiling of murine melanoma progression indicates the reduction of proteins responsible for ROS degradation. Proteomics 6, 1460-1470 (2006).
92. Stockwin LH, Blonder J, Bumke MA et al.: Proteomic analysis of plasma membrane from hypoxia-adapted malignant melanoma. J Proteome Res. 5, 2996-3007 (2006).
93. Zuidervaart W, Hensbergen, PJ, Wong MC et al.: Proteomic analysis of uveal melanoma reveads novel potential markers involved in tumor progression. Invest. Ophthalmol. Vis. Sci. 47, 786-703 (2006).
94. Schick N, Oakeley EJ, Hynes NE, Badache A: TEL/ETV6 is a signal transducer and activator of transcription 3 (Stat3)-induced repressor of Stat3 activity. J. Biol. Chem. 279, 38787-38796 (2004).
95. Mirmohammadsadegh A, Hassan M, Bardenheuer W et al.: STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases. J. Invest. Dermatol. 126, 2272-2280 (2006).
96. Merighi S, Benini A, Mirandola P et al.: A3 adenosine receptor activation inhibits, cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells. J. Biol. Chem. 280, 19516-19526 (2005).
97. Liu G, Zhang F, Lee J, Dong Z: Selective induction of interleukin-8 expression in metastatic melanoma cells by transforming growth factor-β 1. Cytokine 31, 241-249 (2005).
98. Wang C, Wang MW, Tashiro S, Onodera S, Ikejima T: IL-1β acts in synergy with endogenous IL-1β in A375-S2 human melanoma cell apoptosis through mitochondrial pathway. J. Korean Med. Sci. 20, 555-561 (2005).
99. del Olmo M, Alonso-Varona A, Castro B, Bilbao P, Palomares T: Cytomodulation of Interleukin-2 effect by L-2-oxothiazolidine-4-carboxylate on human malignant melanoma. Cancer Immunol. Immunother. 55, 948-957 (2006).
100. Wu H, Goel V, Haluska FG: PTEN signaling pathways in melanoma. Oncogene 22, 3113-3122 (2003).
101. Song J, Wang J, Yang J, Jiang C. Shen W, Wang L: Influence of angiogenin on the growth of A375 human melanoma cells and the expression of basic fibroblast growth factor. Melanoma Res. 16, 119-126 (2006).
102. Hoeflich KP, Gray DC, Eby MT et al.: Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res. 66, 999-1006 (2006).